Olema Oncology is a biopharmaceutical company committed to advancing cancer care, with a particular emphasis on breast cancer. The company is developing innovative therapies, including its lead candidate, palazestrant (OP-1250), a novel oral medication designed to act as a complete estrogen receptor antagonist (CERAN) for the treatment of metastatic breast cancer. Olema's pipeline also features OP-3136, an oral inhibitor targeting the KAT6 pathway. The organization fosters a collaborative and focused environment, aiming to build a dedicated team that values intention and clarity in their mission to create effective medicines tailored to improve patient outcomes. Employees at Olema are encouraged to contribute meaningfully to impactful therapies and participate in a culture that celebrates diversity and excellence while prioritizing ethical standards in their work.